Drug General Information (ID: DDI79Y4GAT)
Drug Name			Thalidomide		Drug Info		Ambenonium		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Immunosuppressive Agents				Antiarrhythmic Agents
Structure

Mechanism of Thalidomide-Ambenonium Interaction (Severity Level: Moderate)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Thalidomide				Ambenonium
Mechanism		Bradycardia				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ambenonium

Recommended Action
Management		Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.